111In-ABD147

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug Name111In-ABD147

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein +[5]

Mechanisms of ActionIonising radiation emittersDelta-like protein 3 modulators

TargetsDelta-like protein 3

Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbdera Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbdera Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantNeuroendocrine Tumors

Other Information

ATC CodeN/A